Experimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Program, Department of Health and Human Services, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA.
Bipolar Disord. 2012 Dec;14(8):880-7. doi: 10.1111/bdi.12003. Epub 2012 Sep 14.
Both ketamine and ethanol are N-methyl-d-aspartate (NMDA) receptor antagonists. Ketamine has rapid antidepressant properties in major depressive disorder (MDD) as well as bipolar depression. In individuals with MDD, a positive family history of alcohol dependence (FHP) was associated with greater improvement in depressive symptoms after ketamine administration compared to individuals whose family history of alcohol dependence was negative (FHN). This study investigated whether FHP influences ketamine's antidepressant and perceptual effects in individuals with bipolar depression.
A post hoc analysis was conducted on 33 subjects with DSM-IV bipolar disorder (BD) type I or II depression pooled from two previously published studies. All subjects had undergone a double-blind, randomized, crossover trial of a single intravenous infusion of ketamine (0.5 mg/kg) combined with lithium or valproate therapy. Subjects were rated at baseline; at 40, 80, 120, and 230 min; and at days 1, 2, 3, 7, 10, and 14 post-infusion. The primary outcome measure was Montgomery-Åsberg Depression Rating Scale (MADRS) scores. Patients were categorized as FHP when they reported at least one first-degree relative with alcohol dependence. Measures of psychosis, dissociation, and dysphoria were also collected.
After ketamine infusion, subjects with FHP showed significantly greater improvement on MADRS scores than FHN subjects. In addition, patients with FHP had attenuated psychotomimetic and dissociative scores compared to FHN patients.
FHP appears to predict a more sustained antidepressant response to ketamine in individuals with BD. Family history of alcoholism may be an important consideration in the development of glutamatergic-based therapies for depression.
氯胺酮和乙醇都是 N-甲基-D-天冬氨酸(NMDA)受体拮抗剂。氯胺酮在重度抑郁症(MDD)和双相抑郁症中具有快速抗抑郁作用。在 MDD 患者中,与家族中没有酒精依赖史(FHN)的患者相比,阳性家族酒精依赖史(FHP)与接受氯胺酮治疗后抑郁症状的改善更大相关。本研究旨在探讨 FHP 是否影响双相抑郁症患者中氯胺酮的抗抑郁和知觉效应。
对来自两项先前发表的研究的 33 名 DSM-IV 双相障碍(BD)I 型或 II 型抑郁症患者进行了事后分析。所有患者均接受了单次静脉输注氯胺酮(0.5mg/kg)联合锂或丙戊酸盐治疗的双盲、随机、交叉试验。患者在基线时;在 40、80、120 和 230 分钟;以及在输注后第 1、2、3、7、10 和 14 天进行评分。主要结局测量指标为蒙哥马利-Åsberg 抑郁评定量表(MADRS)评分。当患者报告至少有一位一级亲属有酒精依赖时,将其归类为 FHP。还收集了精神病、分离和不适的测量值。
在氯胺酮输注后,FHP 患者的 MADRS 评分显著改善,优于 FHN 患者。此外,与 FHN 患者相比,FHP 患者的精神病和分离评分减弱。
FHP 似乎预测 BD 患者对氯胺酮的抗抑郁反应更持久。家族性酒精中毒史可能是开发谷氨酸能为基础的抑郁症治疗方法的重要考虑因素。